Stephen L. Sabba's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 1,000 Common Stock done at an average price of $207.9 . Disclosure was reported to the exchange on March 23, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Sale of securities on an exchange or to another person at price $ 207.87 per share. | 23 Mar 2026 | 1,000 | 32,793 (0%) | 0% | 207.9 | 207,873 | Common Stock |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 33,793 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 01 Apr 2025 | 2,406 | 32,584 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 30,178 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 2,893 | 419 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 2,893 | 30,819 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Sale of securities on an exchange or to another person at price $ 74.30 per share. | 05 Mar 2024 | 1,893 | 28,926 (0%) | 0% | 74.3 | 140,650 | Common Stock |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 26,926 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Sale of securities on an exchange or to another person at price $ 77.13 per share. | 10 May 2023 | 6,408 | 25,784 (0%) | 0% | 77.1 | 494,225 | Common Stock |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 6,408 | 927 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 6,408 | 32,192 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 6,623 | 6,623 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 26,065 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Stephen L. Sabba | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 25,061 (0%) | 0% | 0 | Common Stock |